24 March 2021

Radboudumc researchers, Roderick Maas and Bart van de Warrenburg, theme Disorders of movement, evaluated health-related quality of life, depressive symptoms, fatigue, and physical activity in mildly to moderately affected patients with SCA3, which is the most common inherited spinocerebellar ataxia (SCA) type worldwide. Specifically, they aimed to examine the relationships between patient-reported outcome measures (PROMs) and objective, clinician-based disease severity measures. The results of this study, which was conducted at the Radboudumc Expert Center for Rare and Genetic Movement Disorders, have been published in The Cerebellum on 10 March 2021.

There are exciting therapeutic developments for a number of rare genetic movement disorders, including the dominantly SCAs. Urgent work is needed to reach actual trial-readiness for these disorders. One of the principal dilemmas involves the choice of relevant endpoints that capture meaningful changes in gradually progressive conditions. Commonly used outcome measures include ratings of disease severity by physicians, but these will likely not reflect the actual difficulties patients are facing in daily life. There is currently an increasing interest in PROMs which provide valuable insights into self-perceived health status. PROMs need to be carefully studied, in particular in the early disease stages.

SCA3 patients reported lower quality of life, more depressive symptoms, and higher levels of fatigue than healthy controls. The amount of physical activity did not differ between both groups. Quality of life was primarily determined by fatigue and not by ataxia severity. Depressive symptoms were related to disease duration and fatigue but not to markers of motor disease progression.

Taken together, in early-stage SCA3 patients, decreased quality of life, increased levels of fatigue, and a higher number of depressive symptoms do not merely reflect motor impairment as captured by the commonly used rating scales. The observed discordance between patient-reported and clinician-based outcomes indicates that these measures genuinely evaluate distinct aspects of disease and emphasizes their complementariness in therapeutic trials.


Maas RPPWM, Schutter DJLG, van de Warrenburg BPC. Discordance Between Patient-Reported Outcomes and Physician-Rated Motor Symptom Severity in Early-to-Middle-Stage Spinocerebellar Ataxia Type 3. Cerebellum. 2021 Mar 10. doi: 10.1007/s12311-021-01252-9.

Related news items

Rogier Kievit and Geert Litjens both receive ERC Starting Grant of 1.5 million euros Board of Directors congratulates researchers on top grant

13 January 2022

Researchers Rogier Kievit and Geert Litjens were today festively welcomed by the Board of Directors, because of the ERC Starting Grants they both received. With these European top grants, they can each design an ambitious research project and put together their own research group.

read more

Improved AI will boost cancer research and cancer care Geert Litjens receives ERC Starting Grant

13 January 2022

Geert Litjens from Radboud university medical center has received a European Research Council (ERC) Starting Grant.

read more

Understanding fluctuation variation in cognitive abilities may provide insight into lifelong learning Rogier Kievit recieves ERC Starting Grant

13 January 2022

Rogier Kievit from Radboud university medical center has received a European Research Council (ERC) Starting Grant.

read more

Looking back on RIMLS New Year celebration and awards

12 January 2022

RIMLS organized a special online New Year Celebration, together looking back at the year 2021. René Bindels reviewed 2021 together with Clasien Oomen and Dagmar Eleveld-Trancikova, looked forward towards 2022 and presented the RIMLS awards and several other prizes.

read more

ody composition is more important than BMI for renal cancer survival rates

11 January 2022

Body composition is important for survival rates in renal cell cancer. Research from the Radboudumc shows that low muscle quality and low organ fat are associated with poor survival. This involves different stages of renal cancer, ranging from stage I-III to stage IV.

read more

Giesje Nefs receives fellowship from the Diabetes Fund

10 January 2022

Diabetes technology - such as insulin pumps, closed loop systems, sensors, smart insulin pens - is evolving enormously. But there are also concerns, or false expectations. Giesje Nefs wants to gain more insight into this so she can help people make their choice.

read more